No Data
No Data
Rayon Genomics 2024 Semi-Annual Report
Summary of Ruion Genomics 2024 Semi-Annual Report
Ruian Genetics (688217.SH) released its performance for the first half of the year, with a net income of 9.2218 million yuan, a decrease of 43.20%.
Genon Gene (688217.SH) released its 2024 semi-annual report, with a revenue of 0.135 billion...
Geneplus (688217.SH): net income for the first half of the year was 9.2218 million yuan, a year-on-year decrease of 43.2%.
On August 29th, Gralon announced that it achieved a total operating revenue of 0.135 billion yuan in the first half of 2024, with a year-on-year growth of 5.66%. The net income attributable to the shareholders of the parent company was 9.2218 million yuan, a year-on-year decrease of 43.2%. The basic earnings per share was 0.17 yuan.
Ruiang's net income in the first half of the year dropped by over 40%. The senior management is suspected of illegal operation and is still under investigation for evidence collection.
①Due to the increase in credit impairment losses of accounts receivable and the increase in marketing expenses in sales expenses, Ruiang Gene's net income in the first half of the year fell by 43.20% to 9.2218 million yuan; ②Regarding the alleged illegal operation of multiple senior executives, Ruiang Gene revealed that the relevant evidence collection work is in progress, and the matter is still under further investigation.
Shanghai Rightongene Biotechnology Co., Ltd. (SHSE:688217) Not Doing Enough For Some Investors As Its Shares Slump 28%
No Data
No Data